J. Blaisdell

发表

Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid.

J. Goldstein, D. Zeldin, E. Hodgson, 1998, Archives of biochemistry and biophysics.

Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily.

M. Romkes, J. Goldstein, J. Blaisdell, 1991, Biochemistry.

Isolation of a new canine cytochrome P450 CDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression.

J. Goldstein, S. Bai, J. Blaisdell, 1998, Drug metabolism and disposition: the biological fate of chemicals.

Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18.

J. Goldstein, S. D. de Morais, H. Schweikl, 1993, Biochemical and biophysical research communications.

A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy.

J. Goldstein, J. Blaisdell, N. Limdi, 2009, Blood cells, molecules & diseases.

Losartan and E3174 Pharmacokinetics in Cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 Individuals

J. Goldstein, A. Hinderliter, Craig R. Lee, 2003, Pharmacotherapy.

Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C9*1 heterozygotes

J. Goldstein, A. Hinderliter, Craig R. Lee, 2002, Clinical pharmacology and therapeutics.

A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.

P. Dayer, J. Goldstein, S. Benhamou, 1999, The Journal of pharmacology and experimental therapeutics.

CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases

J. Goldstein, T. Hilliard, Yichun Hu, 2009, European Journal of Clinical Pharmacology.

Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis.

K. Brouwer, J. Goldstein, R. Frye, 2012, British journal of clinical pharmacology.

Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele.

J. Goldstein, Hong-hao Zhou, Zhousheng Xiao, 1997, The Journal of pharmacology and experimental therapeutics.

Differences in the Incidence of the CYP 2 C 19 Polymorphism Affecting the S-Mephenytoin Phenotype in Chinese Han and Bai Populations and Identification of a New Rare CYP 2 C 19 Mutant Allele 1

Hong-Guang Xie, J. Goldstein, Honghao Zhou, 1997 .

An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians.

P. Dayer, J. Goldstein, S. Benhamou, 1998, Pharmacogenetics.

Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. [Erratum to document cited in CA114(15):137136r]

M. Romkes, J. Goldstein, J. Blaisdell, 1993 .

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.

G R Wilkinson, J. Goldstein, S. D. de Morais, 1994, Molecular pharmacology.

Enzyme-Mediated Protein Haptenation of Dapsone and Sulfamethoxazole in Human Keratinocytes: I. Expression and Role of Cytochromes P450

J. Goldstein, E. Schuetz, R. Hines, 2006, Journal of Pharmacology and Experimental Therapeutics.

Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.

P. Dayer, J. Goldstein, U. Meyer, 1998, The Journal of pharmacology and experimental therapeutics.

Identification of New Human CYP 2 C 19 Alleles ( CYP 2 C 19 * 6 and CYP 2 C 19 * 2 B ) in a Caucasian Poor Metabolizer of Mephenytoin 1

P. Dayer, J. Goldstein, U. Meyer, 1998 .

A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.

G R Wilkinson, P. Dayer, J. Goldstein, 1998, The Journal of pharmacology and experimental therapeutics.

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

G R Wilkinson, J. Goldstein, S. D. de Morais, 1994, The Journal of biological chemistry.

Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism.

J. Goldstein, J. Blaisdell, 1996, Methods in enzymology.

Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

J. Goldstein, D. Zeldin, B. Ghanayem, 2001, Pharmacogenetics.

Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs

J. Goldstein, Theresa Klose, J. Blaisdell, 1999, Journal of biochemical and molecular toxicology.

Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.

J. Goldstein, T. Edeki, R S Kidd, 2001, Pharmacogenetics.

Discovery of new potentially defective alleles of human CYP2C9.

H. Mohrenweiser, J. Goldstein, S. Ferguson, 2004, Pharmacogenetics.

Tolbutamide, Flurbiprofen, and Losartan as Probes of CYP2C9 Activity in Humans

J. Goldstein, A. Hinderliter, R. Frye, 2003, Journal of clinical pharmacology.

Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.

M C Meyer, J. Goldstein, A. Straughn, 1999, Pharmacogenetics.

Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes

J. Goldstein, A. Hinderliter, R. Frye, 2003, European Journal of Clinical Pharmacology.

Identification and functional characterization of new potentially defective alleles of human CYP2C19.

H. Mohrenweiser, J. Goldstein, S. Ferguson, 2002, Pharmacogenetics.

Analysis of the CYP2C19 polymorphism in a North-eastern Thai population.

J. Goldstein, W. Tassaneeyakul, W. Tassaneeyakul, 2002, Pharmacogenetics.

Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities.

J. Goldstein, J. Foley, D. Zeldin, 2004, Molecular pharmacology.